Congratulations to the Fall 2017 Growth Fund recipients!
Drs. Michael Detamore & Jakob Townsend
Crosslinking Tissue Particle Hydrogels for Craniofacial Bone Regeneration
Dr. Cortes Williams
Development of In Vitro Tumor Models for Chemotherapeutic Drug Testing
Drs. Adam Duerfeldt, Jian-Xing Ma & Young-Hwa "Henry" Shin
Pre-Clinical Evaluation of Small Molecule Drug Leads for Ocular Microvasculature Diseases
Health Sciences Center
Dr. Robert Eugene Anderson
VLC-FA Treatment of Male Infertility, Skin Disorders, and Neural Development
Drs. Blake Hopiavuori & Dustin Masser
Novel Compositions for Lipid-Mediated Barrier Repair in Atopic Dermatitis
Norman - Spring 2017
Using recombinant genetic engineering, Patrick McKernan and Dr. Harrison are fighting the malaria parasite in new ways. The Growth Fund will support further optimization and testing of their therapy in animal models.
Dr. Cichewicz’s innovation is a safe, effective, and novel chemical method for eliminating the odor of unpleasant smelling thiols (such as skunk smell) and addressing the effects of poison ivy. His Growth Fund project will allow for optimization of this method.
Dr. Rice has developed a therapeutic to combat “superbugs” like methicillin-resistant Staphylococcus aureus (MRSA) that cause dangerous infections. His Growth Fund project will further evaluate efficacy and optimize dosing.
Health Sciences Center - Spring 2017
Dr. Summers has developed a novel inhibitor of retinaldehyde dehydrogenase 2 (RALDH2), a therapeutic target for the control of severe myopia. Her Growth Fund project will further evaluate efficacy and optimize dosing of this novel composition.
Drs. McCarthy and Berry are developing a reproducible, readily accessible model of hypertrophic scarring. The Growth Fund will support further optimization of their prototype and demonstrate proof of concept.
Dr. Webb’s Growth Fund project aims to alleviate painful symptoms associated with inflammatory diseases like lupus. The Growth Fund will support further optimization and testing of her ARID3a inhibitors in animal models.
To combat secondary caries and the failure of dental restorations, Drs. Esteban Florez and Khajotia have created an antibacterial material for inclusion in dental resins that prevents cariogenic biofilms from accumulating. Their Growth Fund project is aimed at optimizing the antibacterial and bioactive behavior of the material.
Questions? Contact Annie Smith, Growth Fund Coordinator, at (405) 325-0719 or firstname.lastname@example.org.